1	Title: Immune response to the mRNA COVID-19 vaccine in hemodialysis patients: cohort study
2	Authors: Yi-Shin Chang ^{1,2} *, Kai Huang ^{1,2} *, Jessica M Lee ^{1,3} , Christen L Vagts ¹ , Christian Ascoli ¹ , Md-Ruhul
3	Amin ¹ , Mahmood Ghassemi ¹ , Claudia M Lora ¹ , Russell Edafetanure-Ibeh ¹ , Yue Huang ¹ , Ruth A Cherian ¹ ,
4	Nandini Sarup ¹ , Samantha R Warpecha ¹ , Sunghyun Hwang ¹ , Rhea Goel ¹ , Benjamin A Turturice ^{1,3,4} , Cody
5	Schott ^{1,3,5} , Montserrat Hernandez ¹ , Yang Chen ^{1,6} , Julianne Joregensen ^{1,2} , Wangfei Wang ^{1,2} , Mladen
6	Rasic ^{1,2} , Richard M Novak ¹ , Patricia W Finn ^{1,2,3**} , David L Perkins ^{1,2,6**}
7	Affiliations:
8	1. Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
9	2. Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois, USA
10	3. Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, Illinois,
11	USA
12	4. Department of Medicine, Stanford University, Palo Alto, California, USA
13	5. Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
14	6. Department of Biological Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
15	*These authors contributed equally.
16	**These authors contributed equally.
17	
18	
19	
20	
21	
22	

23 **Corresponding author:**

- 24 Patricia W. Finn, MD
- 25 840 S. Wood St.
- 26 CSB 1020N, MC 787
- 27 Chicago, IL 60612
- 28 312-413-1279
- 29 pwfinn@uic.edu
- 30
- 31 **Funding:** F30HD102093, F30HL151182, T32HL144909, R01HL138628
- 32 This research has been funded by the University of Illinois at Chicago Center for Clinical and
- 33 Translational Science (CCTS) award UL1TR002003
- 34
- 35 Keywords: RNA Sequencing, COVID-19, Vaccine, SARS-CoV-2, Hemodialysis, binding antibodies,
- 36 neutralizing antibodies
- 37
- 38

39

40 Abstract

Background: End-stage renal disease (ESRD) patients experience immune compromise characterized by
complex alterations of both innate and adaptive immunity, and results in higher susceptibility to
infection and lower response to vaccination. This immune compromise, coupled with greater risk of
exposure to infectious disease at hemodialysis (HD) centers, underscores the need for examination of
the immune response to the COVID-19 mRNA-based vaccines.

46 Methods: A transcriptomic analysis of the immune response to the Covid-19 BNT162b2 mRNA vaccine 47 was assessed in 20 HD patients and cohort-matched controls. RNA sequencing of peripheral blood mononuclear cells (PBMCs) was performed longitudinally before and after each vaccination dose for a 48 49 total of six time points per subject. Anti-spike antibody levels were quantified prior to the first 50 vaccination dose (V1D0) and seven days after the second dose (V2D7) using anti-Spike IgG titers and 51 antibody neutralization assays. Anti-spike IgG titers were additionally quantified six months after initial 52 vaccination. Clinical history and lab values in HD patients were obtained to identify predictors of 53 vaccination response.

54 **Results:** Transcriptomic analyses demonstrated differing time courses of immune responses, with 55 predominant T cell activity in controls one week after the first vaccination dose, compared to 56 predominant myeloid cell activity in HD at this time point. HD demonstrated decreased metabolic 57 activity and decreased antigen presentation compared to controls after the second vaccination dose. 58 Anti-spike IgG titers and neutralizing function were substantially elevated in both controls and HD at 59 V2D7, with a small but significant reduction in titers in HD groups (p < 0.05). Anti-spike IgG remained 60 elevated above baseline at six months in both subject groups. Anti-spike IgG titers at V2D7 were highly 61 predictive of 6-month titer levels. Transcriptomic biomarkers after the second vaccination dose and 62 clinical biomarkers including ferritin levels were found to be predictive of antibody development.

63 Conclusion: Overall, we demonstrate differing time courses of immune responses to the BTN162b2
64 mRNA COVID-19 vaccination in maintenance hemodialysis subjects (HD) comparable to healthy controls
65 (HC) and identify transcriptomic and clinical predictors of anti-Spike IgG titers in HD. Analyzing
66 vaccination as an in vivo perturbation, our results warrant further characterization of the immune
67 dysregulation of end stage renal disease (ESRD).

- 68 **Funding:** F30HD102093, F30HL151182, T32HL144909, R01HL138628
- 69 This research has been funded by the University of Illinois at Chicago Center for Clinical and
- 70 Translational Science (CCTS) award UL1TR002003

71

73

74 Background:

75	End-stage renal disease (ESRD) is the most advanced stage of chronic kidney disease (CKD), with
76	prevalence in the U.S. reaching 809,000 in 2019 ¹ . The most used form of renal replacement therapy for
77	ESRD patients in the U.S. is hemodialysis (HD). Despite significant improvements in hemodialysis
78	technology, the mortality rate in ESRD patients is still as high as 20% annually ² , with infections being the
79	most common cause of hospitalization and mortality after cardiovascular disease ³ . The
80	immunocompromised state of ESRD is characterized by simultaneous immunodepression due to the
81	impact of uremic milieu on immunocompetent cells and immunoactivation due to the accumulation of
82	proinflammatory cytokines ³ . There are alterations to both innate and adaptive immunity, including
83	elevated levels of mannose-binding lectin ⁴ , impaired maturation of monocytes and dendritic cells ^{4,5} ,
84	increased B cell apoptosis ⁶ , and decreased T-cell proliferation with elevated Th1/Th2 ratio ⁷ .

85

86 Studies of genome-wide expression (i.e. transcriptome) profiles of peripheral blood mononuclear cells in 87 ESRD demonstrate a complex picture of immune alterations. One study found upregulation of genes 88 involved in the complement and oxidative metabolism pathways, and downregulation of genes associated with the clathrin-coated vesicle endosomal pathway and T-cell receptor signaling ¹⁰. Two 89 90 other studies have demonstrated impaired expression of genes involved in oxidative phosphorylation 91 and mitochondrial function ^{11,12}. A study identifying a group of inflammatory genes playing a causative 92 role in oxidative stress in dialysis patients showed unique gene expression alterations in maintenance 93 HD patients compared to un-dialyzed CKD patients and compared to patients undergoing peritoneal 94 dialysis ¹³. These studies indicate a range of immune pathways that may impair vaccination response, 95 and further suggest that dialysis leads to unique immune profile alterations. These alterations may lead 96 to higher susceptibility to infection and lower response to vaccination⁸. For example, while more than

97	90% of patients without CKD develop protective antibodies against HBV after vaccination, only 50-60%
98	of patients with ESRD seroconvert. There have also been higher vaccination failure rates demonstrated
99	against influenza virus, Clostridium tetani, and Corynebacterium diphtheriae in ESRD ⁹ .
100	
101	Understanding the immune response to vaccines in ESRD is particularly important for the new mRNA
102	vaccines developed in response to the COVID-19 pandemic. The COVID-19 mRNA-based vaccines,
103	BNT162b2 and mRNA-1273, have proven to be efficacious in non-immunocompromised individuals, with
104	initial reports showing 95% and 94.1% reduction of COVID-19 disease in recipients ^{14,15} . However, certain
105	immunosuppressed populations remain at risk of infection. Given the widespread transmission of
106	COVID-19, detailed assessments of degree, duration, and determinants of immune protection conferred
107	by these vaccines are vitally needed in immunocompromised patient populations including those with
108	ESRD.
109	
110	While recent studies of the SARS-CoV-2 BTN162b2 vaccine in HD demonstrate high levels of
111	seroconversion ranging from 84-96% ^{16–19} , they also demonstrate quantitatively reduced SARS-CoV-2 IgG
112	antibodies. We posit that characterization of the transcriptomic underpinnings of antibody titer
113	development on a continuous scale may identify biomarkers for weaker or less durable immune
114	protection in this population. Furthermore, transcriptomic analyses may identify strategies for the
115	development of new, effective vaccines against other infectious diseases for this population. Thus, we
116	characterized the immune response of the HD population to the COVID-19 mRNA-based BNT162b2
117	vaccine using mRNA sequencing, anti-spike antibody ELISA and neutralization titers across multiple time
118	points. We then integrated these data to identify transcriptomic and clinical determinants of the
119	humoral immune response in HD patients.
120	

121 Methods:

122 Study population and sample acquisition

123	The study was approved by the University of Illinois at Chicago IRB (#2018-1038) Ethics Review
124	Committee. Maintenance HD patients undergoing vaccination with the BNT162b2 mRNA COVID-19
125	vaccine in February 2021 were recruited from the outpatient HD unit at the University of Illinois Hospital
126	(UIH) in Chicago, IL. Control subjects consisted of UIH employees undergoing BNT162b2 mRNA COVID-19
127	vaccination at UIH from December 2020 to January 2021 with no self-reported history of kidney disease
128	or immune disorders. A subset of control subjects matched for age, gender, and COVID-19 history was
129	also analyzed for this study. Blood was collected at 0 – 48 hours prior to and at multiple time points
130	after both the first (V1) and second vaccination doses (V2), which were administered three weeks apart.
131	Control samples were collected prior to each vaccination dose (D0) and at one day (D1) and seven days
132	(D7) after each dose, corresponding to six time points: V1D0, V1D1, V1D7, V2D0, V2D1, V2D7. Blood was
133	collected from HD subjects prior to each vaccination dose and at two days (D2) and seven days after
134	each dose, corresponding to six time points: V1D0, V1D2, V1D7, V2D0, V2D2, V2D7. A final blood sample
135	was drawn six months after initial vaccination (M6) for measurement of antibody titers, prior to
136	additional vaccination doses. Serum and peripheral blood mononuclear cells (PBMCs) were extracted
137	within two hours of blood collection, then stored at -80°C. PBMCs were extracted using density gradient
138	centrifugation at 400g with Ficoll-Paque PLUS. The extracted buffy coat was stored in RNAlater
139	(Invitrogen).

140 Clinical and Demographic Characterization

141 Demographic and clinical data was collected from the electronic health record (EHR) for HD subjects,

142 including medical diagnoses, medications, and laboratory values. Laboratory values included monthly

143 SARS-CoV-2 test results, as well as urea reduction ratio (URR, a measure of dialysis adequacy),

hemoglobin (Hgb), ferritin, transferrin saturation, albumin levels, white blood cell (WBC) count and WBC

145	differential counts obtained during standard of care monthly blood draws for the three months
146	preceding vaccination. Within our analyses, ferritin was coded as either low risk (200ng/ml – 1200
147	ng/ml) or high risk (<200 ng/ml or >1200 ng/ml), since ferritin levels 200ng/ml – 1200 ng/ml have been
148	shown to be associated with lowest all-cause mortality in HD patients ²⁰ . Baseline clinical lab values were
149	calculated as the median of three lab values across the three months prior to vaccination. Demographic
150	and clinical data was collected from a medical questionnaire at time of consent for control subjects, and
151	included medical history, medications, and self-reported prior SARS-CoV-2 positive test results.
152	RNA extraction and RNA Sequencing (RNAseq)
153	RNA sequencing was performed on PBMCs at all V1 and V2 time points for all subjects for whom RNA
154	libraries were successfully built at \geq 5 time points. PBMCs stored in RNAlater were thawed and diluted
155	1:1 with 1X phosphate buffered saline. The mixture was then pelleted and RNA was extracted using the
156	PureLink RNA Mini kit (Invitrogen). DNase treatment to remove genomic DNA contamination was
157	performed using either the PureLink DNase kit or DNA-free DNA Removal Kit (Invitrogen). Purified RNA
158	in sterile water was stored at -80°C. Each RNA sample was quantified using the Qubit RNA High
159	Sensitivity kit (Invitrogen) and Bioanalyzer RNA Pico kit (Agilent) with RIN>=8.
160	For library construction, 50ng of RNA from each sample was aliquoted in 96 well plates. Libraries were
161	generated using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina with the optional
162	NEBNext Poly(A) mRNA Magnetic Isolation Module (New England BioLabs). Each individual sample
163	library was barcoded during PCR amplification using unique dual indexed i5 and i7 primers from the
164	NEBNext Multiplex Oligos for Illumina kit. Each sample library was quantified using the Qubit DNA High
165	Sensitivity kit and Bioanalyzer DNA High Sensitivity kit. Samples were then pooled and sequenced using
166	the MiSeq Nano V2 kit (Illumina) to check read proportions between samples. Samples with lower-than-
167	expected percentage of reads detected were supplemented with an additional spike-in of sample library

to the main pool. The supplemented pooled library was sequenced again using the MiSeq Nano V2 kit to
 verify adequate adjustment. The finalized library was sequenced using a NovaSeq S2 flow cell configured
 for 75bp paired end output.

171 Differential Gene Expression Analysis

172 Raw demultiplexed reads were filtered using fastp to remove adapters and short reads ²¹. Trimmed

173 reads were then quantified using the Salmon pipeline with an hg38 reference transcriptome index ²².

174 Quantified data was imported into R using the tximeta package ²³ to convert Salmon quantification and

175 index data to a count matrix. Transcript names were extracted and matched using Entrez IDs with the

176 AnnotationHub package ²³. This finalized count matrix was then imported into a DESeqDataset object

and normalized using the variance stabilizing transformation in DESeq2.

178 The *DESeq2* R package was used to identify genes that were differentially expressed at each time point

after vaccination for each subject group. Specifically, we implemented a design incorporating group-

180 specific condition effects with individual subjects nested within groups. We performed the classical

181 Deseq2 workflow of estimation of size factors, estimation of dispersion, and negative binomial GLM

fitting for β_i and Wald statistics, increasing the maximum number of iterations for estimation of the

183 negative binomial distribution to 500. We then generated contrasts to obtain differentially expressed

genes for controls at V1D1 and V1D7 (compared to V1D0), and at V2D1 and V2D7 (compared to V2D0).

185 Differentially expressed genes for HD were similarly obtained at V1D2 and V1D7 (compared to V1D0),

and at V2D2 and V2D7 (compared to V2D0). We also directly compared gene expression between

187 controls and HD at V1D7 and at V2D7. The significance threshold to determine differential expression

188 was FDR-adjusted (p < 0.05).

189 Anti-Spike (trimer) IgG Titer Quantification

190 The Human SARS-CoV-2 Spike (Trimer) IgG ELISA Kit from Invitrogen was used to quantitate IgG to the

191 SARS-CoV-2 spike protein in serum samples at V1D0, V2D7, and M6 time points. All samples were

- initially diluted 1:100 (in addition to the 1:10 assay buffer dilution on the 96-well plate) and assayed in
- duplicate, with two-fold serial dilution of the 150,000 units/mL standard control in duplicate for relative
- 194 quantification. Absorbance at 450 nm was quantified using a *Spark*[®] multimode microplate reader.
- 195 Samples that produced signals greater than the upper limit of the standard curve were diluted 1:2000
- and assayed again. IgG concentration was calculated by fitting four-parameter logistic curves to the
- 197 standard controls and taking the average concentrations of duplicates.
- 198 Antibody Neutralization Assays
- 199 Neutralization assays were performed on serum samples from V1D0 and V2D7 using SARS-CoV-2
- 200 pseudotyped virus (pseudovirus). To produce pseudoviruses, an expression plasmid bearing codon-

201 optimized SARS-CoV-2 full length S plasmid was co-transfected into HEK293T cells using the SARS-CoV-2

202 Spike-pseudotyped lentiviral particle Kit (BEI # R-52948). The cell supernatants were collected 72h after

203 transfection, divided into aliquots and cryopreserved at -80 °C.

To titrate the pseudovirus, 5x10³ 293T-ACE2 cells were seeded per well in a 96-well plate in DMEM containing 10% FBS and 1% penicillin streptomycin. Twenty-four hours later, the pseudovirus was diluted 1:10, followed by five-fold serial dilutions for a total of nine dilutions, with each dilution performed in six replicate wells. After incubation at 37 °C and 5% (vol/vol) CO2 for 72h, the luciferase substrate was added to the 96-well plate for chemiluminescence detection. The 50% tissue culture infectious dose (TCID50) of the pseudovirus was calculated according to the Reed-Muench method in the titration macro template ²⁴.

Neutralization activity against SARS-2-CoV was measured in a single-round-of-infection assay with
 pseudoviruses as previously described ²⁵. 5x10³ 293T-ACE2 cells were seeded per well in a 96-well plate.
 Twenty-four hours later, serial dilutions of the serum samples were performed, incubated for one hour

214 at 37 °C with ~1000 TCID50/ml of pseudovirus, then added to monolayers of ACE2-overexpressing 293T 215 cells in guadruplicate. The cell control with cells alone and the virus control (VC) with pseudovirus were 216 set up in each plate. The target cells were incubated for 65h-72h at 37 °C and 5% (vol/vol) CO2. Fifty µL 217 of Bright-Glo, reconstituted following manufacturer's instructions, was added to each well of the 96-well 218 plate and incubated for five minutes at room temperature. The 96-well plate was read by a 96-well luminescence plate reader (Tecan Genius Pro plate reader)²⁶. Percent neutralization was calculated as 219 220 100*([Virus-only control] – [Virus plus serum])/[Virus-only control], and neutralizing titer levels are 221 reported as the serum dilution required to achieve 50% neutralization (50% inhibitory dilution [ID50])²⁷. 222 The input dilution of serum was 1:20, thus 20 is the lower limit of quantification. 223 BTM module enrichment analysis 224 Gene set enrichment analysis was performed for each contrast generated in the DESeg2 analysis above using blood transcription module (BTMs) gene sets ²⁸. BTMs with FDR-adjusted p < 0.05 were considered 225 226 significantly enriched. Enriched BTMs were further characterized using the distribution of Wald statistics 227 of membership genes from DESeq2. To summarize BTM analyses, BTMs were categorized into different 228 families: B cells, cell cycle, dendritic cell/antigen presentation, type I interferon (IFN type I), myeloid activity/inflammation/ T/NK cells, and "others" ²⁹. The percentage of BTMs in each BTM family with 229 significant enrichment at each time point was then quantified over time. 230

231 Statistical analysis of antibody response

To determine the effect of vaccination on anti-spike IgG titers at V2D7 and M6, Kruskal-Wallis tests were performed separately for HD subjects and controls. For each group, anti-spike IgG titer levels were compared to assess for the significant effect of time (V1D0, V2D7, M6), and Wilcoxon rank sum tests were performed with FDR correction to assess significant differences between each pair of time points (V2D7 vs. V1D0, M6 vs. V1D0, M6 vs. V2D7). To determine the effect of vaccination on antibody neutralization activity (ID50) at V2D7, Wilcoxon rank sum tests were performed for each group to
compare V2D7 vs. V1D0.

- 239 Linear models were constructed to establish the effect of prior SARS-CoV-2 infection and subject group
- on anti-spike IgG titer development at V2D7 and M6 and neutralization activity at V2D7. Specifically, log-
- transformed V2D7 anti-spike IgG titers or V2D7 neutralization activity (ID50) were modeled as the
- 242 dependent variable, with subject group (HD or controls), log-transformed V1D0 anti-spike IgG titers or
- 243 V1D0 neutralization activity (ID50), gender, age, race, and ethnicity as independent predictors. To
- 244 determine predictors of anti-spike IgG at six months, a linear model was constructed with the log-
- transformed M6 anti-spike IgG titers as the dependent variable, and V2D7 anti-spike IgG titers, SARS-
- 246 CoV-2 history, gender, age, race, and ethnicity as independent predictors.
- 247 Identification of BTM and clinical predictors of Ab response in HD

248 BTM predictors of antibody response in HD were identified by first calculating a representative 249 expression level of each BTM per sample, which we will refer to as the eigengene. Specifically, the first 250 principal component of each BTM was calculated using DESeq2-derived variance-stabilized gene counts 251 from each module's member genes across the HD V1 time points, and then across the HD V2 time 252 points. Signs (positive or negative) were assigned to the eigengenes such that samples with higher 253 expression of member genes in a BTM would be given a positive sign, while those with lower overall 254 gene expression would be given a negative sign. This was accomplished for each BTM by (1) computing 255 the median gene expression level across membership genes in a given BTM for each sample, (2) 256 computing the Pearson correlation between the eigengene of the BTM and the median gene expression 257 level across all samples, and (3) multiplying the eigengene of the BTM by -1 if the correlation was 258 negative.

259	Subsequently, we constructed linear models with log-transformed anti-spike IgG at V2D7 as the
260	dependent variable and change in BTM eigengene expression after vaccination as the independent
261	variable, controlling for SARS-CoV-2 history. Separate models were constructed for each BTM that was
262	enriched at each time point after vaccination in HD (V1D2 vs V1D0, V1D7 vs V1D0, V2D2 vs V2D0, V2D0
263	V2D7). Change in BTM expression was calculated as the BTM eigengene after vaccination minus the
264	BTM eigengene before vaccination. P-values were FDR-adjusted across number of enriched BTMs per
265	time point.
266	Additionally, baseline clinical laboratory values predictive of antibody response in the HD subjects were
267	identified. Linear models were separately constructed using URR, ferritin (high risk vs low risk),
268	transferrin saturation, hemoglobin, and WBC count to predict log-transformed anti-spike IgG at V2D7
269	and M6.
270	Finally, clinical laboratory values responding to vaccination that predicted antibody titer response in the
271	HD subjects were identified. Linear models were separately constructed using log-fold change (LFC) from
272	baseline measurements of ferritin (continuous instead of binarized low- and high-risk), transferrin
273	saturation, and WBC count to predict log-transformed anti-spike IgG titers at V2D7 and M6.
274	
275	Results:
276	Demographic and Clinical Characterization
277	Demographic and clinical data of the 20 maintenance hemodialysis (HD) and controls (HC) are
278	summarized in Table 1. The racial distribution differed between cohorts with more Black/African
279	American subjects in the HD cohort. The cohorts were otherwise demographically similar. The subjects

280 within the HD cohort had significantly more comorbidities, most notable of which include type 2

- diabetes mellitus (T2DM), hypertension (HTN), dyslipidemia, and other cardiovascular conditions. The
- 282 most common causes of renal failure were T2DM and HTN, with a minority of cases attributed to
- anatomic defects (reflux uropathy) and autoimmune conditions (systemic lupus erythematous and
- 284 idiopathic thrombocytopenic purpura).
- **Table 1. Demographic and clinical data for maintenance hemodialysis and control subjects.**

	Hemodialysis	Control	P-val
Total # of subjects	20	20	
Gender			
Male	11	10	1.0
Female	9	10	1.0
Age (mean (sd))	54 (12)	54 (13)	0.98
Race/Ethnicity			
Black/African American	10	3	0.041
Asian/Pacific Islander	1	2	1.0
White/Caucasian	2	8	0.067
Hispanic/Latinx	7	6	1.0
Other	0	1	1.0
BMI, kg/m ² (mean (sd))	27.8 (5.1)	28.7 (6.4)	0.61
Medical History			
Diabetes	11	1	0.0012
Hypertension	18	4	< 0.001
Other CV disease*	9	0	0.0012
Dyslipidemia	10	0	< 0.001
Autoimmune disease**	3	0	0.23
Immunosuppression***	1	0	1.0
Active Malignancy****	1	0	1.0
Positive COVID-19 History	8	5	0.5

* Includes coronary artery disease (CAD), congestive heart failure (CHF), atrial fibrillation (AF), peripheral
 vascular disease (PVD), and cerebral vascular accent (CVA)

** includes systemic lupus erythematosus (SLE), immune thrombocytopenic purpura (ITP), microscopic
 polyangiitis (MPA)

290 *** hydroxychloroguine

**** defined as malignancy requiring treatment in the last six months; one patient with papillary thyroid
 cancer requiring thyroidectomy, no systemic treatment required

293

294 There were eight HD subjects who previously tested positive for SARS-CoV-2, with positive test dates

ranging from 7 months to four weeks preceding vaccination. Five control subjects self-reported a prior

296 positive SARS-CoV-2 test, with positive test dates ranging from 8 months to four weeks preceding

- 297 vaccination. Detailed clinical characterization of HD subjects is summarized in Table 2. Notable
- laboratory data includes an elevated ferritin from normal (with high population variance), and anemia.

Table 2. Baseline clinical lab values for maintenance hemodialysis patients.

300

	Normal range	Mean (SD)
Kidney/HD status		
Urea Reduction Ratio (URR)	-	0.74 (0.052)
Months on HD	-	46 (44)
Iron		
Ferritin (ng/ml)	10 - 259	838 (550) *
% Transferrin saturation	25 - 50	38 (13)
Albumin	3.4 – 5	4.1 (0.40)
CBC		
WBCs (k/ul)	3.9 - 12	6.0 (2.1)
Hgb (g/dl)	13.2 – 18	10.5 (1.5) *
Lymphocytes (k/ul)	1.3 - 4.2	1.5 (0.7)
Neutrophils (k/ul)	1.3 - 7.5	3.7 (1.5)
Monocytes (k/ul)	0.4 - 1	0.5 (0.2)
Eosinophils (k/ul)	0.2 - 0.5	0.2 (0.2)

301 * indicates value outside of normal range

303	All subjects received two BTN162b2 vaccination doses with the second dose (V2) administered three
304	weeks after the first (V1). Anti-spike IgG binding and neutralizing assay data were obtained for all
305	subjects prior to V1 (V1D0) and seven days after V2 (V2D7). RNA sequencing data was obtained for all
306	control subjects prior to each vaccination dose (D0), and at one day (D1) and seven days (D7) after each
307	dose, corresponding to six time points: V1D0, V1D1, V1D7, V2D0, V2D1, V2D7. One control subject is
308	missing V2D0 data, and one is missing V2D1 data. RNA sequencing data was obtained for 12 HD subjects
309	prior to each vaccination dose, and at two days (D2) and seven days after each dose, corresponding to
310	six time points: V1D0, V1D2, V1D7, V2D0, V2D2, V2D7. Two HD subjects are missing V2D2 data.
311	Sequencing data was not obtained for subjects with fewer than five time points of successfully
312	constructed RNA libraries, due to time points without sample collection or failure to extract high quality

	r 15 HC
--	---------

- 314 subjects and 19 HD subjects. One HD subject tested positive for SARS-CoV-2 14 days after the second
- 315 vaccination dose, demonstrating mild symptoms. None of the other subjects reported SARS-CoV-2
- 316 infection up to 6 months follow up after the second vaccination.
- 317

318 Differential Gene Expression Analysis

- 319 To characterize the molecular basis of immune responses to vaccination in HC and HD, we performed
- 320 differential gene expression analyses of the PBMC RNA sequencing data. There are substantially more
- 321 differentially expressed genes (DEGs) in response to V2 compared to V1, and at D1 and D2 post-
- 322 vaccination compared to D7 (Figure 1). For HC, the largest number of DEGs is found at V2D1, indicating
- 323 the most transcriptional activity immediately after the 2nd vaccine dose, followed by V2D7, V1D1, and
- V1D7. HD follows a similar pattern, with the largest number of DEGs found at V2D2, followed by V2D7,
- 325 V1D2, and V1D7. Notably, HD subjects with no SARS-CoV-2 history (n = 6) have substantially lower
- 326 numbers of DEGs than HD subjects with positive SARS-CoV-2 history (n = 6) at each time point, and
- 327 particularly at V2 time points.



329 Figure 1. Differentially expressed genes (DEGs) increased after second vaccination dose compared to 330 first, and at Day 1 and 2 (D1/D2) compared to Day 7 (D7) for both controls (HC) and maintenance 331 hemodialysis (HD). Number of DEGs at each time point is displayed on a log scale, with DEGs for HC shown for D1 and D7 compared to pre-vaccination time point (D0), and DEGs for HD shown for D2 and 332 333 D7 compared to D0. DEGs are shown independently of SARS-CoV-2 history (Top), for analysis of only subjects with no prior SARS-CoV-2 history (Middle), and for analysis of only subjects with prior SARS-334 335 CoV-2 history (Bottom). The DESeq2 R package was used to identify genes that were differentially 336 expressed at each time point after vaccination for each subject group (p < 0.05, FDR-adjusted).

337

Direct comparison of gene expression between HC and HD with no prior reported SARS-CoV-2 infection
 at V1D7 yielded five DEGs in HD versus HC including increased expression of chemokine CCL19 in HD (p <

340	0.05, FDR-corrected). Comparison of these same groups at V2D7 yielded 18 DEGs including increased
341	expression in HD of TIA1, which encodes a granule-associated protein expressed in cytolytic
342	lymphocytes ³⁰ and natural killer cells, and BH3, a pro-apoptotic Bcl-2 family member and mediator of
343	lymphocyte apoptosis ³¹ .

- 344 Blood Transcription Module (BTM) Enrichment
- 345 BTM enrichment analysis of subjects without SARS-CoV-2 history reveals the vaccine-induced
- progression of various immune processes at each time point after vaccination (Figure 2). Following V1,
- 347 HC demonstrate early (V1D1) enrichment of 29 BTMs, with substantial upregulation of monocyte and
- 348 antiviral IFN activity (TableS1). The immune response transitions to V1D7 enrichment of four BTMs
- 349 including significant T cell activation and downregulation of monocytes (TableS2). Following V2, HC
- demonstrate early (V2D1) enrichment of 82 BTMs, with substantial upregulation of innate antiviral
- activity, similarly to V1D1 (TableS3). The immune response transitions to V2D7 enrichment of ten BTMs,
- with significant upregulation of plasma cells and immunoglobulins (TableS4).









370 Figure S1. Hemodialysis patients (HD) without prior SARS-Cov-2 infection snow increased	i myeloid
---	-----------

- 371 activity at V1D7 and decreased metabolic activity at V2D7 compared to controls (HC). The most
- 372 differentially enriched blood transcription modules (BTMs) between HC and HD with no prior infection
- 373 with SARS-CoV-2 are shown (p < 0.05, FDR-adjusted) at V1D7 and at one week after second vaccination
- dose (V2D7). Density plots for each BTM represent Wald statistics from DESeq2 analysis for each
- 375 membership gene per BTM, with positive Wald statistics indicating increased expression in HC compared
- 376 to HD.
- 377
- 378 While there were no significant BTM enrichments in HC with positive SARS-CoV-2 history, most likely
- due to the insufficient number of subjects, BTM enrichments for HD with positive SARS-CoV-2
- demonstrated notable upregulation of plasma cell activity at V1D7. This contrasts with V1D7 for HD with
- 381 negative SARS-CoV-2, which show primary enrichment of myeloid BTMs (Figure 2). The remainder of
- these enrichments are shown in **Figure S2**.



383

384 Figure S2. Hemodialysis patients (HD) with prior SARS-CoV-2 infection show increased expression of 385 innate and adaptive immune blood transcription modules (BTMs) post-vaccination. The most 386 significantly enriched BTMs are shown (up to six) for Day 2 (D2) and Day 7 (D7) after each vaccination 387 dose (V1, V2) in HD with prior infection with SARS-CoV-2 (p < 0.05, FDR-adjusted). Density plots for each 388 BTM represent Wald statistics from DESeq2 analysis for each membership gene, thereby representing 389 increased or decreased expression per gene at each time point compared to baseline (V1D0 or V2D0). 390

391 Summary enrichments using BTM families show many positive early V1 enrichments of Type 1 IFN 392 activity that dissipate by V1D7 in both HC and HD (Figure 3). However, HC show early positive and

- 393 negative enrichments of myeloid/inflammatory family activity that dissipate by V1D7, while HD show
- many early positive enrichments of myeloid/inflammatory family activity that persist and increase at
- 395 V1D7. Following V2, HC show early predominance of dendritic cell (DC)/antigen presenting cell (APC),
- 396 IFN Type I, and myeloid/inflammatory family activity transitioning to B cell and cell cycle activity at
- 397 V2D7, while HD show predominant early IFN type I family activity transitioning to just one detectable
- 398 cell cycle module enrichment.



Number of enriched BTMs per family, SARS-CoV-2 Hx Negative

400 Figure 3. Controls (HC) and maintenance hemodialysis subjects (HD) demonstrate differing time 401 courses of blood transcription module (BTM) enrichment after each vaccination dose. Percentage of BTMs in each BTM family with significant enrichment at each time point after each vaccination dose (V1, 402 403 V2) for Day 1 (D1) and Day 7 (D7) in HC, and Day 2 (D2) and D7 for HD in subjects with no prior infection 404 with SARS-CoV-2 (p < 0.05, FDR-adjusted). Direction of enrichment was determined using the median 405 Wald statistic from DESeq2 analysis for each BTM membership gene, thereby representing overall 406 increased or decreased expression of membership genes at each time point compared to baseline (V1D0 407 or V2D0).

408 Antibody Binding and Neutralization Assay Response

409 We next aimed to assess immune protection conferred by the vaccine through quantification of anti-410 spike IgG antibodies and functional assessment of neutralizing antibodies. All subjects demonstrated an 411 increase in anti-spike IgG at V2D7, with titers for all subjects except one still elevated above baseline at 412 six months. The exception was one HD subject with prior SARS-CoV-2 infection who demonstrated the 413 highest baseline titers of all subjects prior to vaccination. Both HC and HD subjects demonstrated a 414 statistically significant increase in anti-spike IgG and neutralization activity (ID50) from V1D0 to V2D7 (p 415 < 0.001), followed by an expected decrease at M6 from V2D7 levels (p < 0.001) (Figure 4). Despite this 416 decrease, M6 titers were still increased compared to baseline (p< 0.001).



Figure 4. Antibodies significantly increased_in controls and maintenance hemodialysis (HD) one week after the second vaccination dose (p < 0.001) and six months after initial vaccination (p < 0.001) with the BNT162b2 mRNA COVID-19 vaccine. (A) Anti-spike lgG levels in controls and HD subjects with and without prior SARS-CoV-2 history before vaccination (V1D0), one week after second vaccination dose (V2D7), and six months after initial vaccination (M6). (B) Antibody neutralization activity (ID50) in controls and HD subjects with and without prior SARS-CoV-2 history at V1D0 and V2D7.

424

425 Higher anti-spike IgG at V2D7 was significantly predicted by higher pre-vaccination anti-spike IgG,

426 control group assignment, and younger age (p <0.01, p<0.05, p<0.05, respectively), while gender, race,

427 and ethnicity were not. Higher anti-spike IgG at M6 was significantly predicted by higher V2D7 anti-spike

431	race, and ethnicity.
430	higher pre-vaccination ID50, with no additional predictive value conferred by subject group, age, gender,
429	gender, race, or ethnicity. Higher neutralization activity (ID50) at V2D7 was significantly predicted by
428	lgG (p < 0.001), with no additional predictive value conferred by SARS-CoV-2 history, subject group, age,

- 432
- 433 Transcriptomic and clinical predictors of antibody binding response in HD
- 434 Linear models to predict anti-Spike IgG at V2D7 and at M6 in HD using enriched BTMs, controlling for
- 435 SARS-CoV-2 history, identified BTM predictors at all time points except for V1D2. Of the 18 enriched
- 436 BTMs at V1D7, increased expression (from V1D0) of "LI.M156.1 plasma cells, immunoglobulins" was
- 437 predictive of higher anti-spike IgG at V2D7 (p < 0.05, FDR-corrected), controlling for SARS-CoV-2 history.
- 438 Of the 30 enriched BTMs at V2D2, increased expression of 18 BTMs was predictive of higher anti-Spike
- 439 IgG at V2D7 (p < 0.05, FDR-corrected). These include innate immune, antigen presentation, and T cell
- 440 pathways (Figure 5). Increased expression of "LI.M4.2 PLK1 signaling events" at V2D7 compared to
- 441 V2D0, which was the only enriched module at this time point for HD subjects with no SARS-CoV-2
- 442 history, was predictive of higher anti-spike IgG at both V2D7 and M6 (p < 0.05).



Figure 5. Increased expression of multiple Blood Transcription Modules (BTMs) at V2D2 is predictive
of higher anti-spike IgG at V2D7. Of 30 enriched BTMs at V2D2, increased expression of 18 BTMs is
predictive of increased anti-spike IgG at V2D7 (p< 0.05, FDR-corrected), controlling for SARS-CoV-2
history. Predictive pathways include innate immune, antigen presentation, and T cell pathways. Three
examples are shown.

449





29

464	Figure 6. Baseline ferritin level and post-V1 white blood cell count (WBC) are clinical predictors of
465	post-V2 antibody responses in maintenance hemodialysis patients (HD). (A) Ferritin levels associated
466	with lowest all-cause mortality predict the development of higher anti-spike IgG after vaccination at
467	V2D7 (p < 0.01) and M6 (not shown, p < 0.05) in maintenance HD patients. Dashed vertical lines indicate
468	the intermediate range of ferritin (200-1200 ng/ml) associated with lowest all-cause mortality 20 . (B)
469	Increased WBC after first vaccination dose is predictive of anti-spike IgG titers after vaccination at V2D7
470	(p < 0.01) and M6 (not shown, p < 0.05) in maintenance HD patients. Points with negative log-fold
471	change of white blood cell counts (LFC(WBC)) and positive LFC(WBC) represent a decrease and increase,
472	respectively, in WBC from baseline labs.
473	
171	Discussion
474	
475	Our results demonstrate differing expression of BTMs and differing time courses of immune responses
476	to the BTN162b2 mRNA COVID-19 vaccination in maintenance hemodialysis subjects (HD) compared to
477	controls. Controls demonstrated expected transitions from early Type I interferon and myeloid activity
478	to T cell activity after the first vaccination dose (Figure 2, Figure 3). The predominant positive
479	enrichment of T cell modules in controls at one week after the first vaccination dose (V1D7) was
480	contrasted with predominant positive enrichment of myeloid modules in HD at V1D7. Interestingly, HD
481	showed prolonged upregulation of myeloid activity at V1D7, while controls showed downregulation of
482	these modules at V1D7 (Figure 2, Figure S1). Overall, these observations indicate delayed resolution of
483	innate myeloid responses in the HD cohort.
484	Following the second vaccination dose, both groups demonstrated early enrichment of innate immune
485	modules, with HC alone transitioning to a plasma cell response by V2D7 (Figure 3). Direct group
486	comparisons at V2D7 did not show differences of plasma cell response, but metabolic activity was

487 decreased in HD compared to controls (Figure S1). Further, HD demonstrated increased V2D7 488 expression compared to controls of pro-apoptotic Bcl-2 family member BH3, a mediator of lymphocyte 489 apoptosis. A prior study showed accelerated in vitro apoptosis of lymphocytes in uremia, with a 490 particularly pronounced effect on B cells, mediated by dysregulation of Bcl-2. These results suggest a 491 state of heightened cellular stress in HD after vaccination leading to increased apoptotic signaling. 492 Despite differing transcriptomic time courses in the two group, our results demonstrate significant 493 elevation of anti-spike IgG titers after two doses of BNT162b2 mRNA COVID-19 vaccination in both HD 494 and controls. HD demonstrated only a slight decrease of IgG levels at V2D7 when controlling for SARS-495 CoV-2 history (p < 0.05) and no statistically significant difference at six months. Prior studies comparing 496 short-term antibody response to BNT162b2 mRNA COVID-19 vaccination in HD versus controls find 497 antibody response rates of 84-96% in HD after two vaccination doses, but with lower mean IgG levels 498 compared to controls ^{16–19,32–34}. Notably, the HD population studied here is younger and more racially 499 and ethnically diverse. The average age of HD cohorts in prior studies was predominantly in the 60s, 500 compared to an average age of 54 in our study. Jahn et al. found in a subset analysis that HD patients 501 under 60 years of age responded equally to healthy controls, suggesting an interaction between increasing age and less effective antibody response in HD patients ¹⁷. 502 503 HD subjects with documented SARS-CoV-2 infection prior to vaccination had wider variance of antibody 504 titers at all time points in this study, with two subjects demonstrating V1D0 antibody titer levels similar 505 to that of uninfected subjects. These two subjects consistently had the lowest titer levels at V2D7 and 506 M6 within the group of previously infected subjects and amongst the lowest titers across all subjects.

507 One subject is the oldest enrolled patient, and both are diagnosed with hyperlipidemia.

508 Given previously and presently demonstrated the wider variance of protective immune responses in HD 509 and altered interactions with risk factors including age, it is valuable to identify predictors of the

510 strength of immune response to vaccination in this population. We identified both transcriptomic and 511 clinical predictors of anti-spike IgG development at both V2D7 and six months after the second 512 vaccination dose (M6). Increased gene expression of blood transcription modules (BTMs) including 513 monocyte activity, dendritic cell and antigen presentation activity, IFN type I activity, and T cell 514 activation two days after the second vaccination dose (V2D2) in HD were predictive of V2D7 anti-spike 515 IgG. Additionally, increased expression of PLK1 signaling events, indicating increased cell cycle activity, at 516 V2D7 was predictive of V2D7 and M6 anti-spike IgG. Clinically, serum ferritin values in the intermediate 517 range at baseline predicted stronger anti-spike IgG development. A prior study of 58,058 maintenance 518 HD subjects found serum ferritin levels between 200 and 1200 ng/ml to be associated with lower all-519 cause mortality, due to ferritin <200 ng/ml representing low iron status, and >1200 ng/ml representing a hyper-inflammatory state due to ferritin's status as an acute phase reactant ²⁰. Iron deficiency has been 520 521 linked to impaired immune response and vaccine efficacy in other infections, while inflammation 522 induces macrophage release of the heavy chain component of ferritin, FTH, which has been reported to 523 inhibit lymphocyte proliferation and function ^{34,35}. Additionally, increased LFC in WBC count 1-3 weeks 524 after vaccination was predictive of higher antibody titers. 525 Our study is limited by different early time points between controls and HD (Day 1 vs Day 2 after each

526 vaccination dose) and by sample size, particularly when subdividing SARS-CoV-2 history. The smaller 527 sample size additionally limits our ability to characterize differential immune pathways in clinical subsets 528 of the dialysis population, such as those with low, medium, and high baseline ferritin levels. Future 529 studies are needed for more comprehensive characterization of the immune pathway recruitment in 530 response to the Covid-19 vaccinations in this population. The Covid-19 mRNA vaccines are proving more 531 efficacious than other vaccines in the ESRD population; for example, while more than 90% of patients 532 without chronic kidney disease develop protective antibodies against hepatitis B after vaccination, only 533 50-60% of patients with ESRD seroconvert⁹. One explanation is that, in mRNA vaccines, the mRNA both

534	encodes the viral antigen and acts as an adjuvant due to its innate immunostimulatory properties; the		
535	mRNA is recognized by endosomal and cytosolic innate sensors upon cell entry, resulting in cellular		
536	activation and production of type I interferons and other inflammatory mediators ³⁶ . This elevated		
537	innate immune stimulus could overcome immune desensitization in ESRD, evidenced by diminished		
538	TLR4 expression on monocytes ³⁷ and downregulation of activating receptors on natural killer cells in the second		
539	population ³⁸ . If so, the mRNA vaccine delivery vehicle could prove particularly valuable in vaccine		
540	development for ESRD and HD going forward.		
541	Overa	all, we demonstrate differing time courses of immune responses to the BTN162b2 mRNA COVID-19	
542	vaccination in maintenance hemodialysis subjects (HD) and identify transcriptomic and clinical		
543	predictors of anti-Spike IgG titers in HD. Given the efficacy of this vaccination in our HD cohort, the		
544	differential transcriptomic responses likely represent immune alterations with sub-clinical effects on		
545	humoral immune response to the BTN162b2 mRNA COVID-19 vaccine. Our results warrant further		
546	characterization of the immune dysregulation of ESRD and of immune biomarkers that underlie		
547	efficacious immune responses to vaccination in this population.		
548			
549	Mendeley references		
550 551 552 553	1.	Johansen KL, Chertow GM, Gilbertson DT, et al. US Renal Data System 2021 Annual Data Report: Epidemiology of Kidney Disease in the United States. <i>American journal of kidney diseases : the</i> <i>official journal of the National Kidney Foundation</i> . 2022;79(4 Suppl 1):A8-A12. doi:10.1053/j.ajkd.2022.02.001	
554 555 556	2.	Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. <i>Kidney Int</i> . 2004;66(1):408-418. doi:10.1111/j.1523-1755.2004.00747.x	
557 558	3.	Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. <i>Clin J Am Soc Nephrol</i> . 2008;3(5):1526-1533. doi:10.2215/CJN.00950208	
559 560	4.	Satomura A, Endo M, Ohi H, et al. Significant elevations in serum mannose-binding lectin levels in patients with chronic renal failure. <i>Nephron</i> . 2002;92(3):702-704. doi:10.1159/000064089	

Lim WH, Kireta S, Leedham E, Russ GR, Coates PT. Uremia impairs monocyte and monocyte derived dendritic cell function in hemodialysis patients. *Kidney Int*. 2007;72(9):1138-1148.
 doi:10.1038/sj.ki.5002425

- Fernández-Fresnedo G, Ramos MA, González-Pardo MC, de Francisco AL, López-Hoyos M, Arias
 M. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of
 Bcl-2. Nephrology, dialysis, transplantation : official publication of the European Dialysis and
 Transplant Association European Renal Association. 2000;15(4):502-510.
 doi:10.1093/ndt/15.4.502
- 569 7. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the
 570 altered cytokine network of uremia--the good, the bad, and the ugly. *Kidney Int.*571 2005;67(4):1216-1233. doi:10.1111/j.1523-1755.2005.00200.x
- 5728.Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD573stages 3-4 and hemodialysis patients. Journal of research in medical sciences : the official journal574of Isfahan University of Medical Sciences. 2012;17(6):527-533.
- 5759.Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired576immunity in hemodialysis patients. Semin Dial. 2007;20(5):440-451. doi:10.1111/j.1525-577139X.2007.00283.x
- 57810.Scherer A, Günther OP, Balshaw RF, et al. Alteration of human blood cell transcriptome in579uremia. BMC Med Genomics. 2013;6:23. doi:10.1186/1755-8794-6-23
- 58011.Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients581with chronic kidney disease. BMC Genomics. 2009;10:388. doi:10.1186/1471-2164-10-388
- 58212.Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron583transport chain. J Neurochem. 2002;80(5):780-787. doi:10.1046/j.0022-3042.2002.00744.x
- 58413.Zaza G, Pontrelli P, Pertosa G, et al. Dialysis-related systemic microinflammation is associated585with specific genomic patterns. Nephrology, dialysis, transplantation : official publication of the586European Dialysis and Transplant Association European Renal Association. 2008;23(5):1673-5871681. doi:10.1093/ndt/gfm804
- 588
 14.
 Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

 589
 N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
- 59015.Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19591Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- Grupper A, Sharon N, Finn T, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients
 Undergoing Maintenance Hemodialysis. *Clin J Am Soc Nephrol*. 2021;16(7):1037-1042.
 doi:10.2215/CJN.03500321
- Jahn M, Korth J, Dorsch O, et al. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2
 (Pfizer-BioNTech) in Patients on Hemodialysis. *Vaccines (Basel)*. 2021;9(4).
 doi:10.3390/vaccines9040360

598 599	18.	Attias P, Sakhi H, Rieu P, et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. <i>Kidney Int</i> . 2021;99(6):1490-1492. doi:10.1016/j.kint.2021.04.009
600 601	19.	Anand S, Montez-Rath ME, Han J, et al. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. <i>medRxiv</i> . Published online May 2021. doi:10.1101/2021.05.06.21256768
602 603 604	20.	Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. <i>J Am Soc Nephrol</i> . 2005;16(10):3070-3080. doi:10.1681/ASN.2005040423
605 606	21.	Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. <i>Bioinformatics</i> . 2018;34(17):i884-i890. doi:10.1093/bioinformatics/bty560
607 608 609	22.	Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. <i>Nat Methods</i> . 2017;14(4):417-419. doi:10.1038/nmeth.4197
610 611 612	23.	Love MI, Soneson C, Hickey PF, et al. Tximeta: Reference sequence checksums for provenance identification in RNA-seq. <i>PLoS Comput Biol</i> . 2020;16(2):e1007664. doi:10.1371/journal.pcbi.1007664
613 614	24.	MATUMOTO M. A note on some points of calculation method of LD50 by Reed and Muench. <i>Jpn J Exp Med</i> . 1949;20(2):175-179.
615 616	25.	Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. <i>Nat Protoc</i> . 2020;15(11):3699-3715. doi:10.1038/s41596-020-0394-5
617 618	26.	Ferrara F, Temperton N. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis. <i>Methods Protoc</i> . 2018;1(1). doi:10.3390/mps1010008
619 620	27.	Pegu A, O'Connell SE, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> . 2021;373(6561):1372-1377. doi:10.1126/science.abj4176
621 622 623	28.	Li S, Rouphael N, Duraisingham S, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. <i>Nat Immunol.</i> 2014;15(2):195-204. doi:10.1038/ni.2789
624 625 626	29.	Braun RO, Brunner L, Wyler K, et al. System immunology-based identification of blood transcriptional modules correlating to antibody responses in sheep. <i>NPJ Vaccines</i> . 2018;3:41. doi:10.1038/s41541-018-0078-0
627 628 629	30.	Anderson P, Nagler-Anderson C, O'Brien C, et al. A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. <i>J Immunol</i> . 1990;144(2):574-582.
630 631 632	31.	Labi V, Erlacher M, Kiessling S, et al. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development. <i>J Exp Med</i> . 2008;205(3):641-655. doi:10.1084/jem.20071658
633 634	32.	Agur T, Ben-Dor N, Goldman S, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study. <i>Nephrology, dialysis, transplantation : official</i>
	35	

635 636		publication of the European Dialysis and Transplant Association - European Renal Association. Published online April 2021. doi:10.1093/ndt/gfab155
637 638 639 640	33.	Longlune N, Nogier MB, Miedougé M, et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> . 2021;36(9):1704-1709. doi:10.1093/ndt/gfab193
641 642	34.	Drakesmith H, Pasricha SR, Cabantchik I, et al. Vaccine efficacy and iron deficiency: an intertwined pair? <i>Lancet Haematol</i> . 2021;8(9):e666-e669. doi:10.1016/S2352-3026(21)00201-5
643 644	35.	Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. <i>Int Immunol</i> . 2017;29(9):401-409. doi:10.1093/intimm/dxx031
645 646	36.	Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. <i>Nat Rev Immunol</i> . 2021;21(4):195-197. doi:10.1038/s41577-021-00526-x
647 648 649 650	37.	Koc M, Toprak A, Arikan H, et al. Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. <i>Nephrology, dialysis,</i> <i>transplantation : official publication of the European Dialysis and Transplant Association -</i> <i>European Renal Association</i> . 2011;26(3):955-963. doi:10.1093/ndt/gfq500
651 652	38.	Nagai K. Dysfunction of natural killer cells in end-stage kidney disease on hemodialysis. <i>Ren Replace Ther</i> . 2021;7(1):8. doi:10.1186/s41100-021-00324-0
653		
654 655 656 657	1.	Johansen KL, Chertow GM, Gilbertson DT, et al. US Renal Data System 2021 Annual Data Report: Epidemiology of Kidney Disease in the United States. <i>American journal of kidney diseases : the</i> <i>official journal of the National Kidney Foundation</i> . 2022;79(4 Suppl 1):A8-A12. doi:10.1053/j.ajkd.2022.02.001
658 659 660	2.	Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. <i>Kidney Int</i> . 2004;66(1):408-418. doi:10.1111/j.1523-1755.2004.00747.x
661 662	3.	Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. <i>Clin J Am Soc Nephrol</i> . 2008;3(5):1526-1533. doi:10.2215/CJN.00950208
663 664	4.	Satomura A, Endo M, Ohi H, et al. Significant elevations in serum mannose-binding lectin levels in patients with chronic renal failure. <i>Nephron</i> . 2002;92(3):702-704. doi:10.1159/000064089
665 666 667	5.	Lim WH, Kireta S, Leedham E, Russ GR, Coates PT. Uremia impairs monocyte and monocyte- derived dendritic cell function in hemodialysis patients. <i>Kidney Int</i> . 2007;72(9):1138-1148. doi:10.1038/sj.ki.5002425
668 669 670	6.	Fernández-Fresnedo G, Ramos MA, González-Pardo MC, de Francisco AL, López-Hoyos M, Arias M. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and</i>

671 672		<i>Transplant Association - European Renal Association</i> . 2000;15(4):502-510. doi:10.1093/ndt/15.4.502
673 674 675	7.	Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremiathe good, the bad, and the ugly. <i>Kidney Int</i> . 2005;67(4):1216-1233. doi:10.1111/j.1523-1755.2005.00200.x
676 677 678	8.	Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients. <i>Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences</i> . 2012;17(6):527-533.
679 680 681	9.	Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. <i>Semin Dial</i> . 2007;20(5):440-451. doi:10.1111/j.1525-139X.2007.00283.x
682 683	10.	Scherer A, Günther OP, Balshaw RF, et al. Alteration of human blood cell transcriptome in uremia. <i>BMC Med Genomics</i> . 2013;6:23. doi:10.1186/1755-8794-6-23
684 685	11.	Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. <i>BMC Genomics</i> . 2009;10:388. doi:10.1186/1471-2164-10-388
686 687	12.	Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. <i>J Neurochem</i> . 2002;80(5):780-787. doi:10.1046/j.0022-3042.2002.00744.x
688 689 690 691	13.	Zaza G, Pontrelli P, Pertosa G, et al. Dialysis-related systemic microinflammation is associated with specific genomic patterns. <i>Nephrology, dialysis, transplantation : official publication of the</i> <i>European Dialysis and Transplant Association - European Renal Association</i> . 2008;23(5):1673- 1681. doi:10.1093/ndt/gfm804
692 693	14.	Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>N Engl J Med</i> . 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
694 695	15.	Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>N Engl J Med</i> . 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
696 697 698	16.	Grupper A, Sharon N, Finn T, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. <i>Clin J Am Soc Nephrol</i> . 2021;16(7):1037-1042. doi:10.2215/CJN.03500321
699 700 701	17.	Jahn M, Korth J, Dorsch O, et al. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. <i>Vaccines (Basel)</i> . 2021;9(4). doi:10.3390/vaccines9040360
702 703	18.	Attias P, Sakhi H, Rieu P, et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. <i>Kidney Int</i> . 2021;99(6):1490-1492. doi:10.1016/j.kint.2021.04.009
704 705	19.	Anand S, Montez-Rath ME, Han J, et al. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. <i>medRxiv</i> . Published online May 2021. doi:10.1101/2021.05.06.21256768

706 707 708	20.	Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. <i>J Am Soc Nephrol</i> . 2005;16(10):3070-3080. doi:10.1681/ASN.2005040423
709 710	21.	Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. <i>Bioinformatics</i> . 2018;34(17):i884-i890. doi:10.1093/bioinformatics/bty560
711 712 713	22.	Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. <i>Nat Methods</i> . 2017;14(4):417-419. doi:10.1038/nmeth.4197
714 715 716	23.	Love MI, Soneson C, Hickey PF, et al. Tximeta: Reference sequence checksums for provenance identification in RNA-seq. <i>PLoS Comput Biol</i> . 2020;16(2):e1007664. doi:10.1371/journal.pcbi.1007664
717 718	24.	MATUMOTO M. A note on some points of calculation method of LD50 by Reed and Muench. <i>Jpn J Exp Med</i> . 1949;20(2):175-179.
719 720	25.	Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. <i>Nat Protoc</i> . 2020;15(11):3699-3715. doi:10.1038/s41596-020-0394-5
721 722	26.	Ferrara F, Temperton N. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis. <i>Methods Protoc</i> . 2018;1(1). doi:10.3390/mps1010008
723 724	27.	Pegu A, O'Connell SE, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> . 2021;373(6561):1372-1377. doi:10.1126/science.abj4176
725 726 727	28.	Li S, Rouphael N, Duraisingham S, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. <i>Nat Immunol</i> . 2014;15(2):195-204. doi:10.1038/ni.2789
728 729 730	29.	Braun RO, Brunner L, Wyler K, et al. System immunology-based identification of blood transcriptional modules correlating to antibody responses in sheep. <i>NPJ Vaccines</i> . 2018;3:41. doi:10.1038/s41541-018-0078-0
731 732 733	30.	Anderson P, Nagler-Anderson C, O'Brien C, et al. A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. <i>J Immunol</i> . 1990;144(2):574-582.
734 735 736	31.	Labi V, Erlacher M, Kiessling S, et al. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development. <i>J Exp Med</i> . 2008;205(3):641-655. doi:10.1084/jem.20071658
737 738 739 740	32.	Agur T, Ben-Dor N, Goldman S, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> . Published online April 2021. doi:10.1093/ndt/gfab155
741 742	33.	Longlune N, Nogier MB, Miedougé M, et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. <i>Nephrology, dialysis, transplantation :</i>

743 744		official publication of the European Dialysis and Transplant Association - European Renal Association. 2021;36(9):1704-1709. doi:10.1093/ndt/gfab193
745 746	34.	Drakesmith H, Pasricha SR, Cabantchik I, et al. Vaccine efficacy and iron deficiency: an intertwined pair? <i>Lancet Haematol</i> . 2021;8(9):e666-e669. doi:10.1016/S2352-3026(21)00201-5
747 748	35.	Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. <i>Int Immunol</i> . 2017;29(9):401-409. doi:10.1093/intimm/dxx031
749 750	36.	Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. <i>Nat Rev Immunol</i> . 2021;21(4):195-197. doi:10.1038/s41577-021-00526-x
751 752 753 754	37.	Koc M, Toprak A, Arikan H, et al. Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> . 2011;26(3):955-963. doi:10.1093/ndt/gfq500
755 756	38.	Nagai K. Dysfunction of natural killer cells in end-stage kidney disease on hemodialysis. <i>Ren Replace Ther</i> . 2021;7(1):8. doi:10.1186/s41100-021-00324-0